Key facts
- It has raised $4.0M; the latest was Angel (individual) ($4.0M) in Aug 2025.
- Notable investors include Aidan Gomez, Illia Polosukhin, SK Networks.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for PhnyX Lab
- ·The full record, as it builds
Funding rounds
No funding rounds for PhnyX Lab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhnyX Lab
Developer of a life sciences and engineering generative AI platform designed to simplify complex workflows in pharmaceutical research and engineering design through intelligent automation and natural language interfaces. The company offers a GenAI platform for the pharmaceutical industry and a physics-informed simulation tool for engineers, enabling customers to accelerate drug discovery, clinical trials and engineering design without deep technical expertise.
- Sector
- Information Technology
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Employees
- 23
- Website
- cheiron.bio/
- Ownership
- Privately Held (backing)
PhnyX Lab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhnyX Lab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhnyX Lab in its N-PORT filings yet. We sweep new filings monthly.